Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.37M Sell
22,576
-2,234
-9% -$262K 0.01% 828
2025
Q4
$3.07M Buy
24,810
+2,783
+13% +$332K 0.02% 671
2025
Q3
$2.64M Buy
22,027
+1,470
+7% +$155K 0.02% 641
2025
Q2
$1.89M Buy
20,557
+12,616
+159% +$1.15M 0.01% 697
2025
Q1
$699K Buy
7,941
+1,898
+31% +$187K 0.01% 982
2024
Q4
$563K Buy
6,043
+742
+14% +$71.4K 0.01% 1032
2024
Q3
$492K Buy
5,301
+2,038
+62% +$171K 0.01% 880
2024
Q2
$245K Buy
+3,263
New +$260K 0.01% 782

Other funds holding CRH

&Partners's CRH Position: Q1 2026 in Review

&Partners reduced its CRH (CRH) stake by 9% in Q1 2026, selling an estimated $262K and leaving 22,576 shares worth $2.37M. The position accounts for 0.01% of the portfolio, ranked #828.

&Partners first reported a position in CRH in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.07M in Q4 2025. 1,006 funds tracked by Wall St. Rank hold CRH as of Q1 2026.

  • &Partners held 22,576 shares of CRH worth $2.37M as of Q1 2026.
  • &Partners sold 2,234 CRH shares in Q1 2026, an estimated $262K.
  • CRH made up 0.01% of &Partners's portfolio in Q1 2026, its #828 holding.
  • &Partners first reported a position in CRH in Q2 2024 and has held it in 8 quarters since.
  • &Partners's CRH position peaked at $3.07M in Q4 2025.
  • 1,006 funds tracked by Wall St. Rank held CRH as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.